JP2014506120A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014506120A5 JP2014506120A5 JP2013542255A JP2013542255A JP2014506120A5 JP 2014506120 A5 JP2014506120 A5 JP 2014506120A5 JP 2013542255 A JP2013542255 A JP 2013542255A JP 2013542255 A JP2013542255 A JP 2013542255A JP 2014506120 A5 JP2014506120 A5 JP 2014506120A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- humanized antibody
- chain variable
- variable region
- occupied
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42029110P | 2010-12-06 | 2010-12-06 | |
| US61/420,291 | 2010-12-06 | ||
| US201161446990P | 2011-02-25 | 2011-02-25 | |
| US61/446,990 | 2011-02-25 | ||
| PCT/US2011/063612 WO2012078688A2 (en) | 2010-12-06 | 2011-12-06 | Humanized antibodies to liv-1 and use of same to treat cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017039373A Division JP6453924B2 (ja) | 2010-12-06 | 2017-03-02 | Ｌｉｖ−１に対するヒト化抗体および癌治療のためのその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014506120A JP2014506120A (ja) | 2014-03-13 |
| JP2014506120A5 true JP2014506120A5 (enExample) | 2015-01-08 |
| JP6105481B2 JP6105481B2 (ja) | 2017-03-29 |
Family
ID=46207694
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013542255A Expired - Fee Related JP6105481B2 (ja) | 2010-12-06 | 2011-12-06 | Ｌｉｖ−１に対するヒト化抗体および癌治療のためのその使用 |
| JP2017039373A Active JP6453924B2 (ja) | 2010-12-06 | 2017-03-02 | Ｌｉｖ−１に対するヒト化抗体および癌治療のためのその使用 |
| JP2018233463A Expired - Fee Related JP6869218B2 (ja) | 2010-12-06 | 2018-12-13 | Ｌｉｖ−１に対するヒト化抗体および癌治療のためのその使用 |
| JP2021067924A Active JP7166384B2 (ja) | 2010-12-06 | 2021-04-13 | Ｌｉｖ－１に対するヒト化抗体および癌治療のためのその使用 |
| JP2022170266A Pending JP2023011709A (ja) | 2010-12-06 | 2022-10-25 | Ｌｉｖ－１に対するヒト化抗体および癌治療のためのその使用 |
| JP2024152899A Pending JP2024178209A (ja) | 2010-12-06 | 2024-09-05 | Ｌｉｖ－１に対するヒト化抗体および癌治療のためのその使用 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017039373A Active JP6453924B2 (ja) | 2010-12-06 | 2017-03-02 | Ｌｉｖ−１に対するヒト化抗体および癌治療のためのその使用 |
| JP2018233463A Expired - Fee Related JP6869218B2 (ja) | 2010-12-06 | 2018-12-13 | Ｌｉｖ−１に対するヒト化抗体および癌治療のためのその使用 |
| JP2021067924A Active JP7166384B2 (ja) | 2010-12-06 | 2021-04-13 | Ｌｉｖ－１に対するヒト化抗体および癌治療のためのその使用 |
| JP2022170266A Pending JP2023011709A (ja) | 2010-12-06 | 2022-10-25 | Ｌｉｖ－１に対するヒト化抗体および癌治療のためのその使用 |
| JP2024152899A Pending JP2024178209A (ja) | 2010-12-06 | 2024-09-05 | Ｌｉｖ－１に対するヒト化抗体および癌治療のためのその使用 |
Country Status (25)
| Country | Link |
|---|---|
| US (6) | USRE48959E1 (enExample) |
| EP (4) | EP3461847B1 (enExample) |
| JP (6) | JP6105481B2 (enExample) |
| KR (5) | KR102198189B1 (enExample) |
| CN (1) | CN103533957B (enExample) |
| AU (4) | AU2011338480B8 (enExample) |
| BR (2) | BR112013013781A2 (enExample) |
| CA (2) | CA2819038C (enExample) |
| CY (3) | CY1118874T1 (enExample) |
| DK (3) | DK3461847T3 (enExample) |
| ES (3) | ES2719548T3 (enExample) |
| HR (1) | HRP20170567T1 (enExample) |
| HU (3) | HUE043355T2 (enExample) |
| IL (4) | IL299837A (enExample) |
| LT (1) | LT2648752T (enExample) |
| MX (3) | MX379481B (enExample) |
| NZ (1) | NZ611468A (enExample) |
| PL (3) | PL3461847T3 (enExample) |
| PT (3) | PT3461847T (enExample) |
| RS (1) | RS55843B1 (enExample) |
| RU (1) | RU2608646C2 (enExample) |
| SG (3) | SG10201912646UA (enExample) |
| SI (3) | SI2648752T1 (enExample) |
| WO (1) | WO2012078688A2 (enExample) |
| ZA (1) | ZA201303803B (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX379481B (es) * | 2010-12-06 | 2025-03-11 | Seagen Inc | Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer |
| CN104870475B (zh) | 2012-10-25 | 2019-11-08 | 美国比奥维拉迪维股份有限公司 | 抗补体C1s抗体和其用途 |
| CA2889197A1 (en) | 2012-11-02 | 2014-05-08 | True North Therapeutics, Inc. | Anti-complement c1s antibodies and uses thereof |
| US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
| CN105007941B (zh) | 2012-12-27 | 2019-01-25 | 赛诺菲 | 抗-lamp1抗体和抗体药物偶联物及其用途 |
| MX2016001165A (es) * | 2013-07-31 | 2016-06-29 | Amgen Inc | Estabilizacion de polipeptidos que contienen fragmentos cristalizables. |
| CA3187392A1 (en) | 2013-10-15 | 2015-04-23 | Seagen Inc. | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
| JP6716461B2 (ja) | 2014-02-17 | 2020-07-01 | シアトル ジェネティックス， インコーポレイテッド | 親水性抗体−薬物コンジュゲート |
| PT3280440T (pt) | 2015-04-06 | 2023-02-14 | Bioverativ Usa Inc | Anticorpos anti-c1s humanizados e métodos de utilização destes |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| US11229708B2 (en) | 2015-12-04 | 2022-01-25 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| US20190194338A1 (en) * | 2016-02-17 | 2019-06-27 | Seattle Genetics, Inc. | Bcma antibodies and use of same to treat cancer and immunological disorders |
| KR20220157515A (ko) | 2016-03-15 | 2022-11-29 | 씨젠 인크. | Liv1-adc와 화학요법제를 사용한 병용 요법 |
| MA43835A (fr) | 2016-03-25 | 2018-11-28 | Seattle Genetics Inc | Procédé de préparation de lieurs de médicaments pégylés et leurs intermédiaires |
| WO2017197045A1 (en) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Convergent and enantioselective total synthesis of communesin analogs |
| KR20240010534A (ko) | 2016-08-09 | 2024-01-23 | 씨젠 인크. | 개선된 물리화학적 특성을 갖는 자기 안정화 링커를 구비한 약물 접합체 |
| EA201891851A1 (ru) * | 2016-09-16 | 2019-04-30 | Сиэтл Дженетикс, Инк. | Антитела против bcma и их применение для лечения злокачественных новообразований и иммунологических нарушений |
| CN116554320A (zh) | 2016-10-12 | 2023-08-08 | 美国比奥维拉迪维股份有限公司 | 抗C1s抗体及其使用方法 |
| EA201990890A1 (ru) | 2016-10-18 | 2019-10-31 | Целевая доставка ингибиторов реутилизационного пути никотинамидадениндинуклеотида | |
| MX2019010804A (es) | 2017-03-15 | 2020-01-23 | Silverback Therapeutics Inc | Compuestos de benzazepina, conjugados y usos de los mismos. |
| KR102648564B1 (ko) | 2017-03-24 | 2024-03-19 | 씨젠 인크. | 글루쿠로니드 약물-링커의 제조 공정 및 그 중간물 |
| US11305224B2 (en) | 2017-04-18 | 2022-04-19 | 3M Innovative Properties Company | Air filter media with post-pleat-deposited sorbent particles |
| WO2018201087A1 (en) | 2017-04-27 | 2018-11-01 | Seattle Genetics, Inc. | Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates |
| WO2018209239A1 (en) | 2017-05-11 | 2018-11-15 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| JP2020532543A (ja) * | 2017-09-02 | 2020-11-12 | アッヴィ・インコーポレイテッド | 抗ｅｇｆｒ抗体薬物コンジュゲート（ａｄｃ）及びその使用 |
| CR20200145A (es) * | 2017-09-02 | 2020-08-03 | Abbvie Inc | Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| KR20200090838A (ko) * | 2017-12-01 | 2020-07-29 | 시애틀 지네틱스, 인크. | 유방암 치료를 위한 인간화된 항-liv1 항체 |
| IL276546B2 (en) | 2018-02-20 | 2024-08-01 | Seagen Inc | Hydrophobic auristatin F compounds and their conjugates |
| US20220048895A1 (en) | 2018-09-12 | 2022-02-17 | Silverback Therapeutics, Inc. | Substituted benzazepine compounds, conjugates, and uses thereof |
| SG11202101980VA (en) | 2018-09-12 | 2021-03-30 | Silverback Therapeutics Inc | Methods and composition for the treatment of disease with immune stimulatory conjugates |
| AU2019337652A1 (en) | 2018-09-12 | 2021-03-18 | Silverback Therapeutics, Inc. | Antibody conjugates of toll-like receptor agonists |
| WO2020056194A1 (en) | 2018-09-12 | 2020-03-19 | Silverback Therapeutics, Inc. | Benzazepine compounds, conjugates, and uses thereof |
| CN113015750A (zh) * | 2018-11-07 | 2021-06-22 | 克里斯珀医疗股份公司 | 抗liv1免疫细胞癌症疗法 |
| US20220306727A1 (en) | 2019-06-05 | 2022-09-29 | Seagen Inc. | Methods of Purifying Masked Antibodies |
| WO2020247054A1 (en) | 2019-06-05 | 2020-12-10 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| US20220233709A1 (en) | 2019-06-05 | 2022-07-28 | Seagen Inc. | Masked Antibody Formulations |
| GB201908208D0 (en) * | 2019-06-10 | 2019-07-24 | Univ College Cardiff Consultants Ltd | An anti-mitotic agent |
| EP4004046A1 (en) * | 2019-07-22 | 2022-06-01 | Seagen Inc. | Humanized anti-liv1 antibodies for the treatment of cancer |
| BR112022002720A2 (pt) | 2019-08-15 | 2022-10-11 | Silverback Therapeutics Inc | Formulações de conjugados de benzazepinas e usos das mesmas |
| CA3151322A1 (en) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
| TW202133887A (zh) | 2019-12-09 | 2021-09-16 | 美商西健公司 | 使用liv1-adc及pd-1拮抗劑之組合療法 |
| TWI877278B (zh) | 2019-12-30 | 2025-03-21 | 美商思進公司 | 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法 |
| EP4106819A1 (en) | 2020-02-21 | 2022-12-28 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| IL299508A (en) | 2020-07-01 | 2023-02-01 | Ars Pharmaceuticals Inc | Anti-asgr1 antibody conjugates and uses thereof |
| CA3197158A1 (en) * | 2020-09-28 | 2022-03-31 | Seagen Inc. | Humanized anti-liv1 antibodies for the treatment of cancer |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| WO2022182415A1 (en) | 2021-02-24 | 2022-09-01 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
| KR20230158005A (ko) | 2021-03-18 | 2023-11-17 | 씨젠 인크. | 생물학적 활성 화합물의 내재화된 접합체로부터의 선택적 약물 방출 |
| JP2024516970A (ja) * | 2021-05-07 | 2024-04-18 | サーフィス オンコロジー， エルエルシー | 抗ｉｌ－２７抗体及びその使用 |
| WO2023288236A1 (en) | 2021-07-14 | 2023-01-19 | Seagen Inc. | Antibody masking domains |
| US20240376200A1 (en) | 2021-09-24 | 2024-11-14 | Seagen Inc. | Improved Antibody Masking Domains |
| WO2023111913A1 (en) | 2021-12-15 | 2023-06-22 | Crispr Therapeutics Ag | Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption |
| KR20250044188A (ko) | 2022-05-12 | 2025-03-31 | 하이난 심시어 자이밍 파마슈티컬 컴퍼니 리미티드 | 캄프토테신계 유도체 및 리간드-약물 접합체 |
| WO2024109944A1 (zh) * | 2022-11-25 | 2024-05-30 | 江苏恒瑞医药股份有限公司 | 抗liv-1抗体、其药物偶联物及其医药用途 |
| JP2026506563A (ja) | 2023-02-07 | 2026-02-25 | ラノバ メディシンズ リミテッド | Ｌｉｖ－１を標的とする抗体およびその使用 |
| EP4682168A1 (en) | 2023-03-15 | 2026-01-21 | BioRay Pharmaceutical Co., Ltd. | Anti-liv-1 antibody and anti-liv-1 antibody-drug conjugate, and pharmaceutical use thereof |
| WO2025021118A1 (zh) * | 2023-07-25 | 2025-01-30 | 海南先声再明医药股份有限公司 | 配体-药物偶联物及其偶联连接子 |
| WO2025146137A1 (zh) * | 2024-01-05 | 2025-07-10 | 海南先声再明医药股份有限公司 | 抗liv-1抗体药物偶联物及其用途 |
| WO2025146128A1 (zh) * | 2024-01-05 | 2025-07-10 | 海南先声再明医药股份有限公司 | 抗liv-1的抗体及其用途 |
| CN120040587B (zh) * | 2025-04-27 | 2025-08-08 | 上海宏成药业有限公司 | 抗liv-1抗体或其抗原结合片段及其用途 |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
| US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Acylhydrazone derivatives of anthracycline and methods for their preparation |
| EP0428534B1 (en) | 1988-06-14 | 1995-03-29 | Cetus Oncology Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| ES2087997T3 (es) | 1990-01-12 | 1996-08-01 | Cell Genesys Inc | Generacion de anticuerpos xenogenicos. |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| ES2129454T3 (es) | 1991-08-22 | 1999-06-16 | Becton Dickinson Co | Procedimientos y composiciones de tratamientos de cancer y pronostico de reacciones a los indicados tratamientos. |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| DK0672142T3 (da) | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5914349A (en) | 1994-01-10 | 1999-06-22 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
| CA2132500A1 (en) | 1994-09-20 | 1996-03-21 | David Lockwood Manning | Methods for predicting the behaviour of breast tumours |
| ATE234635T1 (de) | 1995-12-22 | 2003-04-15 | Bristol Myers Squibb Co | Verzweigte hydrazongruppen enthaltende kuppler |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
| WO1998018945A1 (en) | 1996-10-31 | 1998-05-07 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the breast |
| US6066778A (en) | 1996-11-06 | 2000-05-23 | The Regents Of The University Of Michigan | Transgenic mice expressing APC resistant factor V |
| WO1998034118A1 (en) | 1997-01-30 | 1998-08-06 | Yale University | Diagnostic methods and compositions based on the distribution of rad51 |
| EP1027444A1 (en) | 1997-10-31 | 2000-08-16 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the breast |
| WO1999025877A1 (en) | 1997-11-18 | 1999-05-27 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the breast |
| EP1042360A2 (en) | 1997-12-24 | 2000-10-11 | Corixa Corporation | Compounds for immunotherapy and diagnosis of breast cancer and methods for their use |
| JP3422776B2 (ja) | 1998-08-04 | 2003-06-30 | ダイアデクスアス・インコーポレーテッド | 乳癌を診断、監視、病期決定、造影及び治療する新規な方法 |
| ATE386804T1 (de) | 1998-10-15 | 2008-03-15 | Novartis Vaccines & Diagnostic | Gene mit veränderter expression in metastatischen brust- oder dickdarm- krebszellen |
| MXPA01007845A (es) | 1999-02-05 | 2004-06-22 | Samsung Electronics Co Ltd | Metodo para la recuperacion de la textura de imagenes y aparato para el mismo. |
| AU3395900A (en) | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
| US6762020B1 (en) | 1999-03-15 | 2004-07-13 | Protein Design Labs, Inc. | Methods of diagnosing breast cancer |
| US20040141983A1 (en) | 1999-03-15 | 2004-07-22 | Protein Design Labs, Inc. | Compositions against cancer antigen LIV-1 and uses thereof |
| US7285382B2 (en) | 2000-01-25 | 2007-10-23 | Genentech, Inc. | Compositions and methods for treatment of cancer |
| AU2001264099A1 (en) | 2000-06-13 | 2001-12-24 | University College Cardiff Consultants Ltd. | Zinc transporters |
| US6964849B2 (en) | 2001-01-11 | 2005-11-15 | Curagen Corporation | Proteins and nucleic acids encoding same |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| AU2002322280A1 (en) | 2001-06-21 | 2003-01-21 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| WO2003000012A2 (en) | 2001-06-21 | 2003-01-03 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer |
| IL166244A0 (en) | 2001-07-12 | 2006-01-15 | Jefferson Foote | Super humanized antibodies |
| US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| KR101104655B1 (ko) | 2002-03-08 | 2012-01-13 | 애보트 바이오테라퓨틱스 코포레이션 | 암 항원 ｔｍｅｆｆ２ 에 대한 항체 및 이의 용도 |
| DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
| MXPA05007940A (es) * | 2003-01-27 | 2007-06-14 | Biogen Idec Inc | Composiciones y metodos para el tratamiento del cancer usando igsf9 y liv-1. |
| WO2004067564A2 (en) | 2003-01-29 | 2004-08-12 | Protein Design Labs, Inc. | Compositions against cancer antigen liv-1 and uses thereof |
| KR20050010267A (ko) | 2003-07-18 | 2005-01-27 | 삼성전자주식회사 | 식각장치 |
| CN107213469A (zh) | 2003-11-06 | 2017-09-29 | 西雅图基因公司 | 能够与配体偶联的单甲基缬氨酸化合物 |
| US7371381B2 (en) * | 2003-12-12 | 2008-05-13 | Amgen Inc. | Anti-galanin antibodies and uses thereof |
| US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| MX2007000998A (es) | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
| US20060222653A1 (en) * | 2004-11-12 | 2006-10-05 | Xencor, Inc. | Antibodies operably linked to selected chemoattractants |
| WO2006124269A2 (en) * | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
| AU2006287416A1 (en) | 2005-09-07 | 2007-03-15 | Medimmune, Llc | Toxin conjugated Eph receptor antibodies |
| EP2012827A2 (en) | 2006-04-13 | 2009-01-14 | Novartis Vaccines and Diagnostics, Inc. | Methods of treating, diagnosing or detecting cancer |
| DK2099823T4 (da) | 2006-12-01 | 2022-05-09 | Seagen Inc | Målbindingsmiddelvarianter og anvendelser deraf |
| JP2010527916A (ja) | 2007-04-23 | 2010-08-19 | ワイス・エルエルシー | Ｉｌ−１３関連障害を治療する方法および組成物ならびにその治療をモニターする方法 |
| EP2641919A3 (en) * | 2007-11-30 | 2014-05-07 | Glaxo Group Limited | Antigen-binding constructs |
| ES2458541T5 (en) | 2008-05-02 | 2025-08-04 | Seagen Inc | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
| RU2011101378A (ru) | 2008-06-16 | 2012-07-27 | Сайвидон Дайагностикс Гмбх (De) | Алгоритмы предсказания исхода у пациентов с узловой формой рака молочной железы после химиотерапии |
| WO2010045234A1 (en) | 2008-10-14 | 2010-04-22 | University Of Louisville Research Foundation, Inc. | Methods of optimizing treatment of estrogen-receptor positive breast cancers |
| WO2010069858A1 (en) | 2008-12-19 | 2010-06-24 | F. Hoffmann-La Roche Ag | Pharmaceutical composition |
| US8642270B2 (en) | 2009-02-09 | 2014-02-04 | Vm Institute Of Research | Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer |
| US20110165566A1 (en) | 2009-07-09 | 2011-07-07 | Wittliff James L | Methods of optimizing treatment of breast cancer |
| CN102597268B (zh) | 2009-09-03 | 2017-09-22 | 弗·哈夫曼-拉罗切有限公司 | 用于治疗、诊断和监控类风湿性关节炎的方法 |
| MX379481B (es) | 2010-12-06 | 2025-03-11 | Seagen Inc | Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer |
| WO2012125712A2 (en) | 2011-03-14 | 2012-09-20 | Respira Health, Llc | Lung tumor classifier for current and former smokers |
| KR101645905B1 (ko) | 2012-10-12 | 2016-08-04 | 스피로즌 살 | 피롤로벤조디아제핀 및 그의 컨주게이트 |
| KR20220157515A (ko) | 2016-03-15 | 2022-11-29 | 씨젠 인크. | Liv1-adc와 화학요법제를 사용한 병용 요법 |
| KR20200090838A (ko) | 2017-12-01 | 2020-07-29 | 시애틀 지네틱스, 인크. | 유방암 치료를 위한 인간화된 항-liv1 항체 |
| CN113015750A (zh) | 2018-11-07 | 2021-06-22 | 克里斯珀医疗股份公司 | 抗liv1免疫细胞癌症疗法 |
| GB201908208D0 (en) | 2019-06-10 | 2019-07-24 | Univ College Cardiff Consultants Ltd | An anti-mitotic agent |
-
2011
- 2011-12-06 MX MX2017012419A patent/MX379481B/es unknown
- 2011-12-06 DK DK18204152.5T patent/DK3461847T3/da active
- 2011-12-06 DK DK16200557.3T patent/DK3156420T3/en active
- 2011-12-06 ES ES16200557T patent/ES2719548T3/es active Active
- 2011-12-06 CA CA2819038A patent/CA2819038C/en active Active
- 2011-12-06 NZ NZ611468A patent/NZ611468A/en unknown
- 2011-12-06 PL PL18204152T patent/PL3461847T3/pl unknown
- 2011-12-06 CA CA3211246A patent/CA3211246A1/en active Pending
- 2011-12-06 ES ES11847198T patent/ES2620264T3/es active Active
- 2011-12-06 HU HUE16200557A patent/HUE043355T2/hu unknown
- 2011-12-06 SI SI201131155A patent/SI2648752T1/sl unknown
- 2011-12-06 PL PL16200557T patent/PL3156420T3/pl unknown
- 2011-12-06 PT PT182041525T patent/PT3461847T/pt unknown
- 2011-12-06 IL IL299837A patent/IL299837A/en unknown
- 2011-12-06 BR BR112013013781A patent/BR112013013781A2/pt not_active Application Discontinuation
- 2011-12-06 KR KR1020197018015A patent/KR102198189B1/ko active Active
- 2011-12-06 HU HUE18204152A patent/HUE052806T2/hu unknown
- 2011-12-06 ES ES18204152T patent/ES2842895T3/es active Active
- 2011-12-06 SG SG10201912646UA patent/SG10201912646UA/en unknown
- 2011-12-06 KR KR1020237013204A patent/KR20230057485A/ko not_active Ceased
- 2011-12-06 KR KR1020137017660A patent/KR101993921B1/ko active Active
- 2011-12-06 WO PCT/US2011/063612 patent/WO2012078688A2/en not_active Ceased
- 2011-12-06 US US15/862,389 patent/USRE48959E1/en active Active
- 2011-12-06 DK DK11847198.6T patent/DK2648752T3/en active
- 2011-12-06 AU AU2011338480A patent/AU2011338480B8/en active Active
- 2011-12-06 RU RU2013130609A patent/RU2608646C2/ru active
- 2011-12-06 EP EP18204152.5A patent/EP3461847B1/en active Active
- 2011-12-06 EP EP20189823.6A patent/EP3786185A1/en active Pending
- 2011-12-06 HU HUE11847198A patent/HUE031726T2/en unknown
- 2011-12-06 EP EP16200557.3A patent/EP3156420B1/en active Active
- 2011-12-06 PT PT16200557T patent/PT3156420T/pt unknown
- 2011-12-06 SI SI201131705T patent/SI3156420T1/sl unknown
- 2011-12-06 PL PL11847198T patent/PL2648752T3/pl unknown
- 2011-12-06 EP EP11847198.6A patent/EP2648752B1/en active Active
- 2011-12-06 KR KR1020227001675A patent/KR20220011811A/ko not_active Ceased
- 2011-12-06 HR HRP20170567TT patent/HRP20170567T1/hr unknown
- 2011-12-06 SI SI201131936T patent/SI3461847T1/sl unknown
- 2011-12-06 SG SG10201510041QA patent/SG10201510041QA/en unknown
- 2011-12-06 MX MX2013006365A patent/MX351027B/es active IP Right Grant
- 2011-12-06 BR BR122021020513-2A patent/BR122021020513B1/pt active IP Right Grant
- 2011-12-06 JP JP2013542255A patent/JP6105481B2/ja not_active Expired - Fee Related
- 2011-12-06 RS RS20170310A patent/RS55843B1/sr unknown
- 2011-12-06 PT PT118471986T patent/PT2648752T/pt unknown
- 2011-12-06 KR KR1020207037466A patent/KR20200145867A/ko not_active Ceased
- 2011-12-06 CN CN201180058876.6A patent/CN103533957B/zh active Active
- 2011-12-06 US US13/990,778 patent/US9228026B2/en not_active Ceased
- 2011-12-06 LT LTEP11847198.6T patent/LT2648752T/lt unknown
- 2011-12-06 SG SG2013041926A patent/SG190938A1/en unknown
-
2013
- 2013-05-24 ZA ZA2013/03803A patent/ZA201303803B/en unknown
- 2013-06-05 IL IL226754A patent/IL226754B/en active IP Right Grant
- 2013-06-06 MX MX2020010639A patent/MX2020010639A/es unknown
-
2015
- 2015-11-20 US US14/948,183 patent/US9783608B2/en active Active
-
2017
- 2017-03-02 JP JP2017039373A patent/JP6453924B2/ja active Active
- 2017-04-27 CY CY20171100472T patent/CY1118874T1/el unknown
- 2017-06-07 AU AU2017203851A patent/AU2017203851B2/en active Active
- 2017-08-31 US US15/692,424 patent/US20180079810A1/en not_active Abandoned
-
2018
- 2018-09-20 IL IL261900A patent/IL261900A/en unknown
- 2018-12-13 JP JP2018233463A patent/JP6869218B2/ja not_active Expired - Fee Related
-
2019
- 2019-04-11 AU AU2019202530A patent/AU2019202530B2/en active Active
- 2019-04-12 CY CY20191100414T patent/CY1121546T1/el unknown
-
2020
- 2020-02-06 US US16/784,069 patent/US20200165335A1/en not_active Abandoned
- 2020-03-25 IL IL273607A patent/IL273607B2/en unknown
- 2020-12-22 CY CY20201101211T patent/CY1123883T1/el unknown
-
2021
- 2021-04-13 JP JP2021067924A patent/JP7166384B2/ja active Active
- 2021-06-29 AU AU2021204473A patent/AU2021204473B2/en active Active
-
2022
- 2022-10-25 JP JP2022170266A patent/JP2023011709A/ja active Pending
-
2023
- 2023-08-17 US US18/451,744 patent/US20240247059A1/en active Pending
-
2024
- 2024-09-05 JP JP2024152899A patent/JP2024178209A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014506120A5 (enExample) | ||
| KR102236259B1 (ko) | 항-lag-3 항체 및 그것의 사용 | |
| HRP20180269T1 (hr) | Anti-cd40 protutijela, upotrebe i postupci | |
| RU2013130609A (ru) | Гуманизированные антитела к liv-1 и их применение для лечения рака | |
| JP2014531201A5 (enExample) | ||
| JP2019532056A5 (enExample) | ||
| HRP20220811T1 (hr) | Agonistička sredstva za vezanje tnf receptora | |
| JP2010533498A5 (enExample) | ||
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| HRP20210393T1 (hr) | Anti-tfr antitijela i njihova uporaba u liječenju proliferativnih i upalnih poremećaja | |
| RU2016129894A (ru) | Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения | |
| JP2015523380A5 (enExample) | ||
| HRP20201747T1 (hr) | Bispecifične antigen vezujuće molekule koje aktiviraju t stanice, protiv folr1 i cd3 | |
| JP2010526028A5 (enExample) | ||
| KR20160134668A (ko) | Lag-3에 대한 항체 분자 및 그의 용도 | |
| JP2016531915A5 (enExample) | ||
| JP2013121353A5 (enExample) | ||
| JP2015535828A5 (enExample) | ||
| JP2014526898A5 (enExample) | ||
| HRP20221088T1 (hr) | Protutijela i postupci uporabe | |
| HRP20191678T1 (hr) | Pd-1 protutijelo, njegov fragment koji se veže na antigen, i njegova medicinska primjena | |
| HRP20140604T1 (hr) | Sredstva koja djeluju na cd138 i njihova upotreba | |
| RU2014120629A (ru) | Антиген-связывающий белок и его применение в качестве продукта для адресной доставки при лечении рака | |
| JP2014522850A5 (enExample) | ||
| SI2906296T1 (en) | Pyrrolobenzodiazepine-antibody conjugates |